CareCloud, Inc.
NASDAQ:CCLDMedical - Healthcare Information Services
+$0.04 today
- Market cap
- $101.27M
- Beta
- 1.51
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.23
Volume 0.53M
Average 0.58M
CCLD EBITDA Margin
EBITDA as a percentage of revenue.
CareCloud, Inc.NASDAQ: CCLD
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 17.7%
EBITDA Margin was 17.7% in Q1 FY2026, down 2.0 pp from a year earlier. On a trailing-twelve-month basis it was 22.8%, up 1.3 pp year over year. Over 3 fiscal years it widened by 8.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 19.0% for the fiscal year ending Dec 2026, down from 23.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 17.7%-8.4 pp QoQ
- Last fiscal yearDec 2025
- 23.5%+0.9 pp YoY
- LTMMar 2026
- 22.8%+1.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.0 pp | -2.4 pp | -0.4 pp |
| 1 year | +0.9 pp | -4.5 pp | -5.3 pp |
| 3 years | +8.3 pp | +0.5 pp | -7.8 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 23.5%
- Year-over-year change
- +0.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.5% | +0.9pp |
| FY2024 | 2024-12-31 | 22.6% | +49.3pp |
| FY2023 | 2023-12-31 | -26.7% | -41.9pp |
| FY2022 | 2022-12-31 | 15.1% | +1.0pp |
| FY2021 | 2021-12-31 | 14.1% | — |
EBITDA Margin vs competitors
How CCLD compares with its peers on the latest reported figures
- CCLD's LTM Mar 2026 EBITDA Margin of 22.8% is the 2nd highest of the 8 companies compared; the peer median is -131.2%.
- Its year-over-year change of +1.3 pp is the 7th highest of 8, against a peer median of +24.0 pp.
- Over three fiscal years its change of +8.3 pp compares with a peer median of +175.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 102.6% | +184.0 pp | +219.6 pp | |
| LTM Mar 2026 | 22.8% | +1.3 pp | +8.3 pp | |
| LTM Mar 2026 | 5.2% | +4.5 pp | -5.1 pp | |
| LTM Mar 2026 | -4.4% | +24.0 pp | +40.8 pp | |
| LTM Mar 2026 | -131.2% | +8.9 pp | +214.5 pp | |
| LTM Mar 2026 | -427.9% | +95.5 pp | +175.4 pp | |
| LTM Mar 2026 | -859.3% | +600.4 pp | +13170.1 pp | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -874.0% | -638.6 pp | -384.3 pp |
TTRXTurn Therapeutics Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding CCLD) | -131.2% | +24.0 pp | +175.4 pp | |
Competitors are the stored peer set for CCLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.6M | 138.83M | 117.06M | 110.84M | 120.5M |
| Cost of Revenue | 86.92M | 84.43M | 70.82M | 60.84M | 64.46M |
| Gross Profit | 52.68M | 54.39M | 46.24M | 50M | 56.04M |
| Gross Margin | 37.7% | 39.2% | 39.5% | 45.1% | 46.5% |
| Research & Development | 4.41M | 4.4M | 4.74M | 3.78M | 6.38M |
| Selling, General & Admin | 33.06M | 33.61M | 31.11M | 22.36M | 23.2M |
| Operating Expenses | 49.15M | 47.78M | 93.36M | 40.87M | 44.55M |
| Depreciation & Amortization | 16.25M | 15.01M | 16.55M | 16.14M | 16.98M |
| EBITDA | 19.7M | 21.03M | (31.29M) | 25.05M | 28.26M |
| EBITDA Margin | 14.1% | 15.1% | -26.7% | 22.6% | 23.5% |
| Operating Income | 3.53M | 6.61M | (47.12M) | 9.12M | 11.5M |
| Operating Margin | 2.5% | 4.8% | -40.2% | 8.2% | 9.5% |
| Interest Income | 15K | 41K | 154K | 88K | 206K |
| Interest Expense | 455K | 405K | 1.19M | 900K | 287K |
| Other Income / Expenses | (536K) | (1M) | (1.92M) | (1.11M) | (500K) |
| Income Before Tax | 2.99M | 5.61M | (49.04M) | 8.01M | 11M |
| Pre-Tax Margin | 2.1% | 4.0% | -41.9% | 7.2% | 9.1% |
| Income Tax Expense | 157K | 177K | (364K) | 160K | 199K |
| Net Income | 2.84M | 5.43M | (48.67M) | 7.85M | 10.8M |
| Net Margin | 2.0% | 3.9% | -41.6% | 7.1% | 9.0% |
| EPS (Basic) | (0.77) | (0.67) | (4.11) | (0.28) | 0.10 |
| EPS (Diluted) | (0.77) | (0.67) | (4.11) | (0.28) | 0.10 |
| Weighted Avg Shares | 14.54M | 15.11M | 15.67M | 16.15M | 377.92M |
| Weighted Avg Shares (Diluted) | 14.54M | 15.11M | 15.67M | 16.15M | 379.54M |
CareCloud, Inc.
NASDAQ:CCLD
Intrinsic Alpha fair value
Locked
Current Price
$2.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.